CN113151205A - Alcohol dehydrogenase mutant and application thereof in cyclic terpene ketone synthesis - Google Patents
Alcohol dehydrogenase mutant and application thereof in cyclic terpene ketone synthesis Download PDFInfo
- Publication number
- CN113151205A CN113151205A CN202110421331.2A CN202110421331A CN113151205A CN 113151205 A CN113151205 A CN 113151205A CN 202110421331 A CN202110421331 A CN 202110421331A CN 113151205 A CN113151205 A CN 113151205A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- seq
- alcohol dehydrogenase
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010021809 Alcohol dehydrogenase Proteins 0.000 title claims abstract description 85
- 102000007698 Alcohol dehydrogenase Human genes 0.000 title claims abstract description 85
- -1 cyclic terpene ketone Chemical class 0.000 title claims abstract description 19
- 235000007586 terpenes Nutrition 0.000 title claims abstract description 15
- 238000003786 synthesis reaction Methods 0.000 title abstract description 18
- 230000015572 biosynthetic process Effects 0.000 title abstract description 16
- 238000003259 recombinant expression Methods 0.000 claims abstract description 27
- 238000006356 dehydrogenation reaction Methods 0.000 claims abstract description 20
- 230000003197 catalytic effect Effects 0.000 claims abstract description 17
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 9
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 9
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 9
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 3
- 150000001413 amino acids Chemical group 0.000 claims description 73
- 108090000790 Enzymes Proteins 0.000 claims description 36
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 229930182817 methionine Natural products 0.000 claims description 33
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 31
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 31
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 31
- 239000004474 valine Substances 0.000 claims description 31
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 26
- 235000013922 glutamic acid Nutrition 0.000 claims description 26
- 239000004220 glutamic acid Substances 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 22
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 20
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 16
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 14
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 13
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 13
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 12
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 150000002440 hydroxy compounds Chemical class 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims 2
- 150000002742 methionines Chemical group 0.000 claims 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 239000013604 expression vector Substances 0.000 abstract description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 5
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 57
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 29
- 238000000034 method Methods 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 229960004873 levomenthol Drugs 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- XMGQYMWWDOXHJM-SNVBAGLBSA-N (-)-α-limonene Chemical compound CC(=C)[C@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-SNVBAGLBSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229930027917 kanamycin Natural products 0.000 description 8
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 8
- 229960000318 kanamycin Drugs 0.000 description 8
- 229930182823 kanamycin A Natural products 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- ULDHMXUKGWMISQ-SECBINFHSA-N (-)-carvone Chemical compound CC(=C)[C@@H]1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-SECBINFHSA-N 0.000 description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000005515 coenzyme Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229940041616 menthol Drugs 0.000 description 6
- 150000002741 methionine derivatives Chemical group 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 229960003595 (-)- limonene Drugs 0.000 description 5
- 101710088194 Dehydrogenase Proteins 0.000 description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108010088986 Camphor 5-Monooxygenase Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102220608429 Mitogen-activated protein kinase kinase kinase kinase 1_E95V_mutation Human genes 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102220512974 Probable JmjC domain-containing histone demethylation protein 2C_E97M_mutation Human genes 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 4
- 150000003668 tyrosines Chemical class 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000012867 alanine scanning Methods 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Natural products CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- RMIANEGNSBUGDJ-RKDXNWHRSA-N (+)-cis-isopulegone Chemical compound C[C@@H]1CC[C@H](C(C)=C)C(=O)C1 RMIANEGNSBUGDJ-RKDXNWHRSA-N 0.000 description 2
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 2
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- NFLGAXVYCFJBMK-BDAKNGLRSA-N (-)-menthone Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-BDAKNGLRSA-N 0.000 description 2
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000007036 catalytic synthesis reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010008618 limonene-3-hydroxylase Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000037039 plant physiology Effects 0.000 description 2
- 238000012257 pre-denaturation Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- CIJQGPVMMRXSQW-UHFFFAOYSA-M sodium;2-aminoacetic acid;hydroxide Chemical compound O.[Na+].NCC([O-])=O CIJQGPVMMRXSQW-UHFFFAOYSA-M 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 1
- YSMPVONNIWLJML-FXQIFTODSA-N Ala-Asp-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(O)=O YSMPVONNIWLJML-FXQIFTODSA-N 0.000 description 1
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 1
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 1
- LNNSWWRRYJLGNI-NAKRPEOUSA-N Ala-Ile-Val Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O LNNSWWRRYJLGNI-NAKRPEOUSA-N 0.000 description 1
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 1
- XRUJOVRWNMBAAA-NHCYSSNCSA-N Ala-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 XRUJOVRWNMBAAA-NHCYSSNCSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- BGGAIXWIZCIFSG-XDTLVQLUSA-N Ala-Tyr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O BGGAIXWIZCIFSG-XDTLVQLUSA-N 0.000 description 1
- PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 1
- DHONNEYAZPNGSG-UBHSHLNASA-N Ala-Val-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 DHONNEYAZPNGSG-UBHSHLNASA-N 0.000 description 1
- FEZJJKXNPSEYEV-CIUDSAMLSA-N Arg-Gln-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O FEZJJKXNPSEYEV-CIUDSAMLSA-N 0.000 description 1
- YKZJPIPFKGYHKY-DCAQKATOSA-N Arg-Leu-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKZJPIPFKGYHKY-DCAQKATOSA-N 0.000 description 1
- YVTHEZNOKSAWRW-DCAQKATOSA-N Arg-Lys-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O YVTHEZNOKSAWRW-DCAQKATOSA-N 0.000 description 1
- QEYJFBMTSMLPKZ-ZKWXMUAHSA-N Asn-Ala-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QEYJFBMTSMLPKZ-ZKWXMUAHSA-N 0.000 description 1
- ZZXMOQIUIJJOKZ-ZLUOBGJFSA-N Asn-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O ZZXMOQIUIJJOKZ-ZLUOBGJFSA-N 0.000 description 1
- WLVLIYYBPPONRJ-GCJQMDKQSA-N Asn-Thr-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O WLVLIYYBPPONRJ-GCJQMDKQSA-N 0.000 description 1
- LMIWYCWRJVMAIQ-NHCYSSNCSA-N Asn-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N LMIWYCWRJVMAIQ-NHCYSSNCSA-N 0.000 description 1
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 1
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 1
- OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 description 1
- SJLDOGLMVPHPLZ-IHRRRGAJSA-N Asp-Met-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SJLDOGLMVPHPLZ-IHRRRGAJSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- SMEYEQDCCBHTEF-FXQIFTODSA-N Cys-Pro-Ala Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O SMEYEQDCCBHTEF-FXQIFTODSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 1
- RLZBLVSJDFHDBL-KBIXCLLPSA-N Glu-Ala-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RLZBLVSJDFHDBL-KBIXCLLPSA-N 0.000 description 1
- PXHABOCPJVTGEK-BQBZGAKWSA-N Glu-Gln-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O PXHABOCPJVTGEK-BQBZGAKWSA-N 0.000 description 1
- HPJLZFTUUJKWAJ-JHEQGTHGSA-N Glu-Gly-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HPJLZFTUUJKWAJ-JHEQGTHGSA-N 0.000 description 1
- JXYMPBCYRKWJEE-BQBZGAKWSA-N Gly-Arg-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JXYMPBCYRKWJEE-BQBZGAKWSA-N 0.000 description 1
- GVVKYKCOFMMTKZ-WHFBIAKZSA-N Gly-Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)CN GVVKYKCOFMMTKZ-WHFBIAKZSA-N 0.000 description 1
- QPDUVFSVVAOUHE-XVKPBYJWSA-N Gly-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(O)=O QPDUVFSVVAOUHE-XVKPBYJWSA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 1
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- HKSNHPVETYYJBK-LAEOZQHASA-N Gly-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CN HKSNHPVETYYJBK-LAEOZQHASA-N 0.000 description 1
- COZMNNJEGNPDED-HOCLYGCPSA-N Gly-Val-Trp Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O COZMNNJEGNPDED-HOCLYGCPSA-N 0.000 description 1
- DXUJSRIVSWEOAG-NAKRPEOUSA-N Ile-Arg-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N DXUJSRIVSWEOAG-NAKRPEOUSA-N 0.000 description 1
- AZEYWPUCOYXFOE-CYDGBPFRSA-N Ile-Arg-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)O)N AZEYWPUCOYXFOE-CYDGBPFRSA-N 0.000 description 1
- RMIANEGNSBUGDJ-UHFFFAOYSA-N Isoisopulegone Natural products CC1CCC(C(C)=C)C(=O)C1 RMIANEGNSBUGDJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-LPEHRKFASA-N Isomenthol Natural products CC(C)[C@@H]1CC[C@H](C)C[C@H]1O NOOLISFMXDJSKH-LPEHRKFASA-N 0.000 description 1
- MJOZZTKJZQFKDK-GUBZILKMSA-N Leu-Ala-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(N)=O MJOZZTKJZQFKDK-GUBZILKMSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- VFQOCUQGMUXTJR-DCAQKATOSA-N Leu-Cys-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)O)N VFQOCUQGMUXTJR-DCAQKATOSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- JDBQSGMJBMPNFT-AVGNSLFASA-N Leu-Pro-Val Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O JDBQSGMJBMPNFT-AVGNSLFASA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- GTAXSKOXPIISBW-AVGNSLFASA-N Lys-His-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N GTAXSKOXPIISBW-AVGNSLFASA-N 0.000 description 1
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 1
- YUAXTFMFMOIMAM-QWRGUYRKSA-N Lys-Lys-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O YUAXTFMFMOIMAM-QWRGUYRKSA-N 0.000 description 1
- IKXQOBUBZSOWDY-AVGNSLFASA-N Lys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCCN)N IKXQOBUBZSOWDY-AVGNSLFASA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- DTICLBJHRYSJLH-GUBZILKMSA-N Met-Ala-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O DTICLBJHRYSJLH-GUBZILKMSA-N 0.000 description 1
- SMVTWPOATVIXTN-NAKRPEOUSA-N Met-Ser-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SMVTWPOATVIXTN-NAKRPEOUSA-N 0.000 description 1
- DSZFTPCSFVWMKP-DCAQKATOSA-N Met-Ser-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN DSZFTPCSFVWMKP-DCAQKATOSA-N 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 101001041023 Nicotiana tabacum 2-alkenal reductase (NADP(+)-dependent) Proteins 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- LDSOBEJVGGVWGD-DLOVCJGASA-N Phe-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 LDSOBEJVGGVWGD-DLOVCJGASA-N 0.000 description 1
- HATVCTYBNCNMAA-AVGNSLFASA-N Pro-Leu-Met Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O HATVCTYBNCNMAA-AVGNSLFASA-N 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- HKHCTNFKZXAMIF-KKUMJFAQSA-N Ser-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=C(O)C=C1 HKHCTNFKZXAMIF-KKUMJFAQSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- DDPVJPIGACCMEH-XQXXSGGOSA-N Thr-Ala-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DDPVJPIGACCMEH-XQXXSGGOSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- XGEUYEOEZYFHRL-KKXDTOCCSA-N Tyr-Ala-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 XGEUYEOEZYFHRL-KKXDTOCCSA-N 0.000 description 1
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229930007646 carveol Natural products 0.000 description 1
- 108010005658 carveol dehydrogenase Proteins 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 239000007986 glycine-NaOH buffer Substances 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
- C12P7/26—Ketones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention relates to an alcohol dehydrogenase mutant and application thereof in cyclic terpene ketone synthesis. In particular to an alcohol dehydrogenase mutant with obviously improved catalytic performance, a coding nucleic acid thereof, a recombinant expression vector and a recombinant expression transformant containing the nucleic acid sequence, and application of catalyzing dehydrogenation reaction of hydroxyl compounds by utilizing the alcohol dehydrogenase mutant or the recombinant expression transformant, in particular to the dehydrogenation reaction of cyclic terpene alcohol with 3-and 6-positions of hydroxyl groups to prepare cyclic terpene ketone. Compared with wild alcohol dehydrogenase, the alcohol dehydrogenase mutant has certain improvement on the dehydrogenation activity of series of hydroxyl compounds, and has good application prospect.
Description
Technical Field
The invention belongs to the technical field of bioengineering, and particularly relates to an alcohol dehydrogenase mutant with obviously improved catalytic performance, a coding nucleic acid thereof, a recombinant expression vector and a recombinant expression transformant containing the nucleic acid sequence, and application of the alcohol dehydrogenase mutant or the recombinant expression transformant in catalyzing dehydrogenation reactions of hydroxyl compounds, particularly in catalyzing dehydrogenation reactions of cyclic terpene alcohols with hydroxyl groups at 3-and 6-positions to prepare cyclic terpene ketones.
Background
L- (-) -menthol, also called levomenthol, is liquid at room temperature, has poor water solubility, a cool flavor and a certain fragrance, and is often used in the processing of alcoholic beverages, condiments, oral health products, cosmetics and other products (Phytochemistry,2013,96: 15-25). In nature, (-) -menthol is present in oil gland secretory cells of mint plant leaves and can be obtained by extraction, atmospheric distillation, etc. (Proc. Natl. Acad. Sci. U.S.A,1999,97: 2934-2939). Menthol consumption has increased dramatically in recent years, and by 2018, (-) -menthol has consumed up to about 4 ten thousand tons (anhui. chem. ind.,2018), of which about 70% is distilled from plant mint and is greatly influenced by factors such as weather, land, and manpower. About 30% of (-) -menthol is synthesized chemically. So far, the market of the (-) -menthol in our country is large, but the large-area planting production area of the menthol in our country is less, so that the natural (-) -menthol used in the industries of food and the like is mostly imported from India and Brazil. So far, no menthol chemical method synthesis enterprise with high yield and good technology exists in China.
The current chemical synthesis of (-) -menthol is unique to both Takasago, Japan, and Symrise, Germany. The Japanese Takasago enterprise synthesizes (-) -menthol (chem.Biodvers, 2014,11: 1688-; the company Symrise, Germany, prepares (-) -menthol by enantiomeric resolution (US 20100249467A 1,2010). However, both of them have disadvantages that the former catalyst is expensive and seriously contaminated, and the latter catalyst is difficult to be separated and has more loss. Both enterprises Takasago and Symrise, Germany were removed, leaving the chemical synthesis method on a smaller scale (CN 107056587B, 2017).
Since the (-) -menthol obtained by plant extraction and chemical synthesis methods still cannot meet the market demand, the biological synthesis method of the (-) -menthol attracts more and more attention of scholars. However, the biosynthesis of (-) -menthol is still in its initial stage, and most of them is the preparation of (-) -menthol by kinetic resolution of racemic menthol derivatives (Tetrahedron asymmetry, 2003,14: 3313-3319). At present, the effect is more remarkable that the menthyl acetate is resolved by fixing esterase of the bacillus subtilis in an aqueous two-phase system, the loading capacity of a substrate can be improved to 3M, and meanwhile, the conversion rate of more than 40 percent and the e.e. value of 97 percent are ensured, so that the mass production of the L-menthol becomes possible (adv. Synth. Catal.,2010,351: 405-. However, these methods are not synthesized from inexpensive compounds such as glycerol and (-) -limonene, and face the same difficulties as the plant extraction method of (-) -menthol (Research on Chemical Intermediates,2018,44: 6847-. Thus, it is more likely that efficient biosynthesis of (-) -menthol can be achieved in microorganisms that mimic the de novo synthetic pathway of (-) -menthol in plants (Journal of Biological Chemistry,1992,267: 7582-7587).
Although the current approach to de novo construction of (-) -menthol in microorganisms has not been realized, excellent progress has been made. The subject group of Nigel S.Scrutton couples the last two steps in the menthol pathway, alkene reductase (NtDBR) and (-) -menthone reductase (MMR) are simultaneously constructed into Escherichia coli, (-) -menthol is successfully synthesized from (+) -pulegone through a one-pot enzymatic method, and the last two steps in the (-) -menthol biosynthesis pathway (ACS Synth.biol.,2015,4:1112-1123) are opened, so that the in vitro menthol construction pathway is hopeful. Subsequently in 2018, the group achieved the synthesis of (-) -menthol (25.5mg/L) from (+) -cis-isopulegone by replacing isopulegone isomerase (IPGI) with bacterially derived isomerase (KSI). In addition to 2014, the Andrea Schmid task group succeeded in de novo synthesis of 2.7g/L of (-) -limonene in E.coli (Biotechnol. J.,2014,9:1000-1012), so that the bottlenecks of the (-) -menthol pathway of the present microorganisms are limonene-3-hydroxylase (L3H) and isopnthenol dehydrogenase (IPDH).
Isomenthenol dehydrogenase (IPDH) belongs to the SDR superfamily. Such enzymes can catalyze the oxidation of isomenthol to the corresponding ketone. This enzyme was originally found in plants of the genus Mentha (Archives of Biochemistry)&Biophysics,1985,238:49-60), which is capable of catalyzing the oxidation of both isopenthenol (isoperienol) and carveol (carvacol), and is therefore also known as an isopenthenol/carveol dehydrogenase (Plant Physiology,2004,136: 4215-4227). In 2005, the enzyme in peppermint was successfully heterologously expressed and characterized in E.coli, but its viability was very low, kcat/KmOnly 0.027s-1·mM-1. In addition, the enzyme was found in other plants (biol. pharm. Bull.,2014,37:847-852), microorganisms (Journal of Biological Chemistry,1999,274:26292-26304), fungi (Fungal Biology,2017,121: 137-144). However, most of these isomenthenol dehydrogenases have not characterized the substrate isomenthenol, and the crystal structure of the enzyme has not been resolved at present.
IPDH is known to provide a new method for the future synthesis of isomenthenone, besides having an important role in the microbial synthesis pathway of (-) -menthol. Isomenthenone, which can be used as an "alarm" for warning mites from being away (Agricultural and Biological Chemistry,1987,51:3441-3442), is an important substance in the Biological world, and although other applications of the isopenthenone are unknown at present, more applications of the isopenthenone are discovered along with improvement of a method for synthesizing the isopenthenone. So far, The research on The preparation of isomenthenone has been still shallow, and only chemical synthesis methods exist, such as The oxidation of (-) -limonene to (-) -isomenthenone by ruthenium, pyrrole complexes (The Journal of Organic Chemistry,1999,64: 7365-. The only preparation to achieve the gram scale was the method used in the topic group of Nigel s.scrutton (j.nat. prod.,2018,81: 1546-. In conclusion, the current method for synthesizing the isomenthenone by the enzyme method has not appeared.
In summary, IPDH occupies an important position in the microbial synthesis route of (-) -menthol and the preparation of isomenthenone, but known isomenthenol dehydrogenase MpIPDH has the problems of low catalytic activity, existence in the form of membrane protein, low space-time yield and the like. Therefore, there is a need for enzyme catalysts with better catalytic performance to meet the needs of efficient menthol synthesis pathways in microorganisms and the needs of enzymatic synthesis of isomenthenone.
Disclosure of Invention
The invention aims to solve the technical problem of providing an alcohol dehydrogenase mutant with obviously improved catalytic performance aiming at the defects of the isomenthenol dehydrogenase in the prior art.
According to one technical scheme of the invention, the alcohol dehydrogenase mutant with obviously improved catalytic performance is obtained.
First, protein BLAST was carried out using MpIPDH (Plant Physiology,2005,137:863-872, NCBI Number: Q5C919.1) reported as a probe in the bacterial bank at NCBI to obtain a sequence having a certain homology to MpIPDH. Secondly, after the homologous sequences are compared, the sequences of related bond motif are screened out, wherein the key motif is such as SDR catalytic triad (Ser-Tyr-Lys), NAD (P)+Binding to motif (- (T) GXXXXGXG-), SDR conserved motif (NNAG) and NAD+-a dependent binding residue Asp; deleting sequences with high homology between every two sequences to ensure that the homology between every two sequences is less than 85 percent, thereby obtaining the enzyme library of the alcohol dehydrogenase. Through activity detection of candidate enzyme, screening to obtain reductase PaIPDH derived from Pseudomonas aeruginosa, and the amino acid sequence of the reductase PaIPDH is shown in a sequence table SEQ ID No. 2.
In the invention, the enzyme gene is used as a female parent, and is subjected to directed evolution modification by adopting strategies such as alanine scanning, crystal structure guidance, site-specific saturation mutation, iterative combinatorial mutation and the like, and an alcohol dehydrogenase mutant with obviously improved activity and thermal stability is identified and obtained by combining with an activity detection rescreening of an ultraviolet spectrophotometer method.
The alcohol dehydrogenase mutant is a derivative protein obtained by replacing 1 or more amino acid residues in 95 th glutamic acid, 97 th glutamic acid, 154 th methionine, 189 th valine, 191 th aspartic acid, 194 th methionine, 195 th phenylalanine, 199 th tyrosine and 208 th phenylalanine of an amino acid sequence shown as SEQ ID No.2 with other amino acid residues; meanwhile, the derived protein has higher catalytic performance and stability than the protein consisting of the amino acid sequence shown in SEQ ID No. 2.
Compared with wild alcohol dehydrogenase, the alcohol dehydrogenase mutant provided by the invention has higher catalytic activity and stability effect.
The present invention also encompasses proteins derived by replacing other amino acid residues with other amino acid residues that do not affect the catalytic performance of the alcohol dehydrogenase mutant.
The present invention provides various preferred alcohol dehydrogenase mutants, which are proteins consisting of any one of the following amino acid sequences:
(1) replacing glutamic acid at position 95 of the amino acid sequence shown as SEQ ID No.2 with valine (E95V);
(2) the glutamic acid at position 95 of the amino acid sequence shown as SEQ ID No.2 is replaced by phenylalanine (E95F);
(3) the glutamic acid at position 97 of the amino acid sequence shown as SEQ ID No.1 is replaced by methionine (E97M);
(4) the methionine at position 154 of the amino acid sequence shown as SEQ ID No.2 is replaced by histidine (M154H);
(5) replacing valine at position 189 of the amino acid sequence shown as SEQ ID No.2 with tryptophan (V189W);
(6) replacing valine at position 189 of the amino acid sequence shown as SEQ ID No.2 with isoleucine (V189I);
(7) replacing aspartic acid at position 191 of the amino acid sequence shown as SEQ ID No.2 with valine (D191V);
(8) substitution of methionine at position 194 of the amino acid sequence shown in SEQ ID No.2 with lysine (M194K);
(9) substitution of methionine at position 194 of the amino acid sequence shown in SEQ ID No.2 with asparagine (M194N);
(10) replacing phenylalanine at position 195 of the amino acid sequence shown as SEQ ID No.2 with tryptophan (F195W);
(11) replacing phenylalanine at position 195 of the amino acid sequence shown as SEQ ID No.2 with methionine (F195M);
(12) substitution of tyrosine 199 to valine (Y199V) of the amino acid sequence shown in SEQ ID No. 2;
(13) replacing tyrosine 199 th of the amino acid sequence shown as SEQ ID No.2 with histidine (Y199H);
(14) replacing glutamic acid at position 95 of the amino acid sequence shown as SEQ ID No.2 with valine (E95V), and replacing phenylalanine at position 208 with histidine (F208H);
(15) the glutamic acid at position 97 of the amino acid sequence shown as SEQ ID No.2 is replaced by methionine (E97M), and the methionine at position 154 is replaced by histidine (M154H);
(16) the methionine at position 194 of the amino acid sequence shown as SEQ ID No.2 is replaced by lysine (M194K), and the tyrosine at position 199 is replaced by serine (Y199W);
(17) substitution of methionine at position 194 with lysine (M194K), substitution of tyrosine at position 199 with histidine (Y199H), substitution of phenylalanine at position 208 with histidine (F208H) of the amino acid sequence shown in SEQ ID No. 2;
(18) the amino acid sequence shown in SEQ ID No.2 has the amino acid sequence with glutamic acid at position 95 substituted by phenylalanine (E95F), valine at position 189 substituted by tryptophan (V189W), phenylalanine at position 195 substituted by tryptophan (F195W) and tyrosine at position 199 substituted by valine (Y199V).
The alcohol dehydrogenase mutant provided by the invention is suitable for being used as an isomenthenol dehydrogenase mutant.
The second technical scheme of the invention provides nucleic acid for coding the alcohol dehydrogenase mutant and a recombinant expression vector containing the nucleic acid sequence of the alcohol dehydrogenase mutant gene.
The nucleic acid codes for the expression of an evolutionarily engineered alcohol dehydrogenase mutant according to claim one, the source of which comprises: cloning the gene sequence of the series of alcohol dehydrogenase mutants in the technical scheme I by using a genetic engineering technology; or obtaining the nucleic acid molecule for coding the alcohol dehydrogenase mutant according to the technical scheme one by a method of artificial complete sequence synthesis.
The recombinant expression vector can be constructed by connecting the coding nucleic acid sequence of the alcohol dehydrogenase mutant gene of the invention to various commercially available empty vectors by a conventional method in the field. The commercially available empty vector may be any plasmid vector conventional in the art, so long as the recombinant expression vector can normally replicate in a corresponding expression host and express the corresponding alcohol dehydrogenase.
The preferred plasmid vectors are different for different expression hosts. It will be clear to one of ordinary skill in the art how to select appropriate vectors, promoters, enhancers and host cells. For E.coli hosts, the plasmid vector is preferably the pET-28a (+) plasmid. The recombinant expression vector of the escherichia coli can be prepared by the following method: the alcohol dehydrogenase mutant gene fragment obtained by PCR amplification is subjected to double digestion by using restriction enzymes EcoR I and Hind III, meanwhile, an unloaded plasmid pET-28a (+) is subjected to double digestion by using the restriction enzymes EcoR I and Hind III, the DNA fragment of the alcohol dehydrogenase mutant subjected to the enzyme digestion and the unloaded plasmid are recovered, and the DNA fragment and the unloaded plasmid are connected by using T4 DNA ligase to construct a recombinant expression vector containing the encoding nucleic acid of the alcohol dehydrogenase mutant for escherichia coli expression.
The third technical scheme of the invention provides a recombinant expression transformant containing the alcohol dehydrogenase mutant gene or the recombinant expression vector thereof. The recombinant expression transformant can be prepared by transforming an already constructed recombinant expression vector into a host cell.
The host cell is a variety of conventional host cells in the art, so long as the recombinant expression vector is capable of stably self-replicating and efficiently expressing a protein of interest upon induction by an inducing agent. Coli BL21(DE3) is preferred as the host cell for the efficient expression of the alcohol dehydrogenase mutant of the present invention.
The fourth technical scheme of the invention provides a recombinant alcohol dehydrogenase mutant catalyst, which is in any one of the following forms:
(1) culturing the recombinant expression transformant of the present invention, and isolating a transformant cell containing the alcohol dehydrogenase mutant;
(2) culturing the recombinant expression transformant of the present invention, and isolating a crude enzyme solution containing the alcohol dehydrogenase mutant;
(3) and (3) freeze-drying the crude enzyme solution of the alcohol dehydrogenase mutant to obtain crude enzyme powder.
The culture method and conditions for the recombinant expression transformant may be methods and conditions that are conventional in the art. In one embodiment of the present invention, the following steps are provided: culturing the recombinant expression transformant of the present invention to obtain a recombinant alcohol dehydrogenase. For recombinant E.coli, the preferred medium is LB medium: 10g/L of peptone, 5g/L of yeast extract, 10g/L of NaCl and 6.5-7.0 of pH. The preferred culture method is: the recombinant Escherichia coli constructed as described above was inoculated into LB medium containing kanamycin and cultured overnight at 37 ℃ with shaking at 180 rpm. Inoculating to 500mL Erlenmeyer flask containing 100mL LB medium (containing kanamycin) at an inoculum size of 1-2% (v/v), shaking and culturing at 37 deg.C and 180rpm, when OD of culture solution is600When the concentration reaches 0.6-0.8, adding isopropyl-beta-D-thiogalactoside (IPTG) with the final concentration of 0.1-0.5mmol/L as an inducer, inducing at 16 ℃ for 16-24h, centrifuging the culture solution, collecting the precipitate, and then washing twice with physiological saline to obtain the recombinant expression transformant cell. And freeze-drying the harvested recombinant cells to obtain freeze-dried cells containing the alcohol dehydrogenase mutant. Suspending the harvested recombinant cells in 5-10 times (v/w) volume of buffer solution, ultrasonically disrupting, centrifuging, and collectingSupernatant fluid, namely obtaining crude enzyme liquid of the recombinant alcohol dehydrogenase mutant. And (3) freezing the collected crude enzyme solution at-80 ℃, and then drying at low temperature by using a vacuum freeze dryer to obtain freeze-dried enzyme powder. The obtained freeze-dried enzyme powder is stored in a refrigerator at 4 ℃ and can be conveniently used.
The activity determination method of the alcohol dehydrogenase mutant comprises the following steps: containing 1mmol/L (-) -trans-isomenthenol and 10mmol/L NAD+Preheating 1mL of reaction system (50mmol/L glycine-sodium hydroxide buffer solution, pH10.0) to 40 ℃, then adding a proper amount of alcohol dehydrogenase mutant, carrying out heat preservation reaction at 40 ℃, detecting the absorbance change of NADH at 340nm on a spectrophotometer, and recording the change value of absorbance within 1 minute.
The enzyme activity is calculated by the following formula:
enzyme activity (U) ═ EW × V × 103(6220X l) wherein EW is the change in absorbance at 340nm in 1 minute; v is the volume of the reaction solution, and the unit is mL; 6220 the molar extinction coefficient of NADH, expressed in L/(mol. cm); l is the path length in cm. 1 enzyme activity unit (U) is defined as 1. mu. mol NAD catalytically reduced per minute under the above conditions+The amount of enzyme required.
The fifth technical scheme of the invention provides application of the alcohol dehydrogenase mutant or the recombinant alcohol dehydrogenase mutant catalyst in catalyzing dehydrogenation reaction of hydroxyl compounds.
Namely, the present invention provides a method for preparing a corresponding ketone by catalyzing a dehydrogenation reaction of a hydroxy compound using an alcohol dehydrogenase mutant or a recombinant alcohol dehydrogenase mutant catalyst.
Wherein the hydroxy compound may be selected from any one of the following compounds:
in the application, the concentration of the hydroxyl compound can be 1-5 mmol/L, and the dosage of the alcohol dehydrogenase mutant in the alcohol dehydrogenase mutant or the recombinant alcohol dehydrogenase mutant catalyst can be 1-50U/mmol of the hydroxyl compound.
In one embodiment of the present invention, there is provided a use of the alcohol dehydrogenase mutant or the recombinant alcohol dehydrogenase mutant catalyst for catalyzing a dehydrogenation reaction of a cyclic terpene alcohol having hydroxyl groups at 3-and 6-positions to prepare a cyclic terpene ketone.
In one embodiment of the invention, the cyclic terpene ketones include (-) -isomenthenone, (-) -carvone.
In one embodiment of the invention, the use of the alcohol dehydrogenase mutant or recombinant alcohol dehydrogenase mutant catalyst in catalyzing the dehydrogenation of (-) -trans-isomenthenol to produce (-) -isomenthenone is provided.
In one embodiment of the present invention, NADH or NAD is present in the reaction solution+The amount of the compound is 0.1 to 0.5 mmol/L. O can be utilized in the reaction process2As co-substrate, NAD in the reaction system is realized by reaction catalyzed by NADH dehydrogenase+The coenzyme (2) is circulated, and the phosphate buffer solution of the reaction system is a phosphate buffer solution conventional in the art, such as potassium phosphate buffer solution, and the concentration thereof is preferably 50 mmol/L. The dehydrogenation reaction is carried out under the condition of shaking or stirring. The temperature of the dehydrogenation reaction is 20-40 ℃, and preferably 25 ℃. The time of the dehydrogenation reaction is based on the time of complete conversion of the substrate or self termination of the reaction, and the reaction time is preferably less than 24 h.
In the course of its use in catalyzing the dehydrogenation of (-) -trans-isomenthenol to prepare (-) -isomenthenone, the direct preparation of (-) -isomenthenone from (-) -trans-isomenthenol is not desirable due to the commercial unpreferability of the substrate (-) -trans-isomenthenol. Thus (-) -isomenthenone is synthesized indirectly by introducing a hydroxylation step. The method specifically comprises the following steps: passing through P450camY96F/Y247L(chem. Commun.,2001, 635-doped 636) and the indispensable electron transfer parts Pdx and PdR thereof are co-expressed on ampicillin-resistant pET21a, cheap and cheap (-) -limonene can be mostly hydroxylated into (-) -trans-isopnthrenol, and then the (-) -trans-isopnthrenol generated in the previous hydroxylation step is oxidized into (-) -isopnthrenol through the protein expressed by the kanamycin-resistant pET28a-PaIPDH mutant. Due to the fact thatFor this reason, the first step in the cascade enzyme method, P450cam, is partly consuming NADH to produce NAD+While the second step, PaIPDH mutant, consumes NAD+Generating NADH, namely self-circulating coenzyme. Thus, no external helper enzyme is required to circulate the coenzyme. And through whole cell reaction, the activity of P450 can be kept to the maximum extent without adding coenzyme NAD+/NADH。
Wherein, the reaction process of the alcohol dehydrogenase mutant and P450cam combined transformation for synthesizing (-) -isomenthenone (compound 3a) is shown in figure 1.
In which the protein P450cam is coexpressedY96F/Y247LThe DNA sequence of the-Pdx-PdR is shown as a sequence table SEQ ID No. 3.
After the oxidation reaction is finished, separating and extracting the oxidation product cyclic terpene ketone in the reaction liquid by a conventional method.
The method for separating and extracting the oxidation product cyclic terpene ketone in the reaction liquid is preferably that ethyl acetate is added into the reaction liquid for extraction, anhydrous sodium sulfate is added into an organic phase obtained by extraction for overnight drying, and due to the volatility of the product, an extraction liquid is concentrated by a reduced pressure distillation method at 20-25 ℃ to remove the solvent, so that a crude product of the product ketone is obtained. Preferably, the crude ketone product is separated by silica gel column chromatography, 200-300 mesh silica gel is adopted, and the eluent is petroleum ether: ethyl acetate 50: 1 (or 100:1), after the elution is finished, detecting the purity by GC, then collecting and combining elution tubes meeting the purity requirement, removing the solvent by a reduced pressure distillation method, and purifying to obtain the pure product of the target (-) -isomenthenone.
Compared with the prior art, the invention has the following innovation and improvement effects:
the invention provides an alcohol dehydrogenase mutant with better catalytic performance, which can efficiently catalyze the hydroxyl dehydrogenation reaction of cyclohexane 3 site-/6 site-alcohol to prepare optically pure ketone compounds such as: (-) -isomenthenone and (-) -carvone. The (-) -isomenthenone and the (-) -carvone are cyclic terpene ketone compounds, and the cyclic terpene ketone compounds have unique fragrance and antibacterial and anticancer effects, so that the cyclic terpene ketone compounds have wide application in the fragrance market and the medicine marketAnd (4) value. The alcohol dehydrogenase can catalyze the conversion of hydrophobic (-) -trans-iso-menthenol substrate with the concentration as high as 8mM, the conversion rate of more than 80 percent is realized, and the yield reaches 128.6mg L-1Is the highest yield of the current enzyme method for synthesizing (-) -isomenthenone. Compared with parent alcohol dehydrogenase PaIPDH, the alcohol dehydrogenase mutant obtained by the invention has the advantages of higher catalytic activity, high stability and the like, so that the mutant is more suitable for construction of a high-efficiency (-) -menthol synthesis way in microorganisms and has a great prospect.
Drawings
FIG. 1 is a schematic diagram of the reaction process of the alcohol dehydrogenase mutant of the present invention and P450cam combined transformation to synthesize (-) -isomenthenone (compound 3 a).
Detailed Description
The individual reaction or detection conditions described in the context of the present invention may be combined or modified according to common general knowledge in the art and may be verified experimentally. The technical solutions and technical effects of the present invention will be clearly and completely described below with reference to the specific embodiments, but the scope of the present invention is not limited to these embodiments, and all changes or equivalent substitutions that do not depart from the spirit of the present invention are included in the scope of the present invention.
The material sources in the following examples are:
the genome Pseudomonas aeruginosa contains a nucleic acid sequence shown in a sequence table SEQ ID No.1 and is extracted in a laboratory where the inventor is located.
The empty plasmid vector pET28a was purchased from Novagen.
Coli BL21(DE3) competent cells, PrimeSTAR (HS), Taq DNA polymerase, agarose gel DNA recovery kits were purchased from Beijing Tiangen Biochemical technology Ltd.
The restriction enzymes EcoR I, Hind III are all commercially available from New England Biolabs (NEB).
In the examples, mM is abbreviated as mmol/L.
Unless otherwise indicated, specific experiments in the following examples were performed according to methods and conditions conventional in the art, or according to the commercial instructions of the kits.
Example 1 construction of alcohol dehydrogenase PaIPDH
The PCR technology is adopted to construct alcohol dehydrogenase PaIPDH with an amino acid sequence shown as a sequence table SEQ ID No. 2.
The primers used were:
the sequence of the upstream primer is as follows: CCGGAATTCATGAGCAAACTTCTTTCCGGCCAGG are provided.
The sequence of the downstream primer is as follows: CCCAAGCTTTCAGATCGCCGTCGC are provided.
Wherein, the GAATTC sequence in the upstream primer is the enzyme cutting site of EcoR I, and the AAGCTT sequence in the downstream primer is the enzyme cutting site of Hind III.
PCR was carried out using 2 XTaq DNA polymerase using the genome Pseudomonas aeruginosa as a template. PCR System (20. mu.L): 2 XTaq DNA polymerase 10. mu.L, upstream and downstream primers (10. mu.M) 1. mu.L each, DMSO 1. mu.L, genomic Pseudomonas aeruginosa 2. mu.L, and sterilized distilled water to make up to 20. mu.L. PCR reaction procedure: (1) pre-denaturation at 94 ℃ for 10 min; (2) denaturation at 94 deg.C for 1 min; (3) annealing at 55 ℃ for 30 s; (4) extending for 1min at 72 ℃; carrying out 30 cycles in all of the steps (2) to (4); finally, extension is carried out for 10min at 72 ℃, and the product is stored at 4 ℃. And (3) carrying out agarose gel electrophoresis analysis and verification on the PCR product, then carrying out gel cutting, purification and recovery, and carrying out double digestion on the recovered target gene DNA fragment and the unloaded plasmid pET28a for 6h at 37 ℃ by using restriction enzymes EcoR I and Hind III respectively. The double restriction products are analyzed and verified by agarose gel electrophoresis, then the gel is cut, purified and recovered, and the obtained linearized pET28a plasmid and the purified target gene DNA fragment are placed at 16 ℃ for overnight connection by using T4 DNA ligase. The ligation product was transformed into E.coli BL21(DE3) competent cells, and uniformly spread on LB agar plates containing 50. mu.g/ml kanamycin, and placed in an incubator at 37 ℃ for static culture for about 12 hours.
The transformants on the transformation plates were pipetted into 4mL LB tubes and incubated overnight at 37 ℃ on a 220rpm shaker. After the sequencing verification, 50% of glycerol is added for bacterium preservation, so that pET28a-PaIPDH recombinant bacteria are obtained.
Example 2 semi-rational design construction of alcohol dehydrogenase PaIPDH mutant
On the basis of example 1, PaIPDH and its coenzyme NAD+Carrying out the proteinCrystallization yields PaIPDH-NAD+And (3) crystal compound, wherein a PaIPDH structure is subjected to molecular docking with a substrate molecule, and then alanine scanning is carried out on amino acids near a substrate pocket. With the assistance of software such as Pymol, Swiss-model, Autodockvina and the like, in the spatial stereo structure of alcohol dehydrogenase PaIPDH of an amino acid sequence shown in a sequence table SEQ ID No.2, amino acid residues around a binding site of a substrate (-) -trans-isoperienol comprise: glutamic acid at position 95, glutamic acid at position 97, glutamine at position 98, methionine at position 154, valine at position 189, aspartic acid at position 191, threonine at position 192, methionine at position 194, phenylalanine 195, tyrosine at position 199, phenylalanine at position 208. After sensitive sites are obtained from alanine scanning, the activity of the enzyme is further improved through site-directed saturation mutation and combined mutation. Site-directed mutagenesis is carried out on the amino acid residues at the sites by using a site-directed mutagenesis technology.
The primers used are shown in table 1:
TABLE 1 primer Table
PCR amplification was performed using PrimeStar (HS) premix using pET28a-PaIPDH as a template. The PCR system is as follows: 2 XPrimeStar HS premix 10 uL, upstream and downstream primers 1 uL, pET28a-PaIPDH plasmid 40ng, DMSO1 uL, adding sterile distilled water to make up to 20 uL. PCR reaction procedure: (1) pre-denaturation at 95 ℃ for 3 min; (2) denaturation at 98 ℃ for 10 s; (3) annealing at 55 ℃ for 15 s; (4) extending for 6min and 20s at 72 ℃; carrying out 18 cycles in all of the steps (2) to (4); finally, extension is carried out for 10min at 72 ℃. After the reaction, 1. mu.L of restriction enzyme Dpn I and 2. mu.L of 2 XCutsmart were added to 20. mu.L of PCR product, and the mixture was incubated at 37 ℃ for 2 hours to digest and degrade the template sufficiently, and the digested product was transformed into E.coli BL21(DE3) competent cells, spread uniformly on LB agar plates containing 50. mu.g/ml kanamycin, and left to stand in a 37 ℃ incubator for about 12 hours. The obtained monoclonal colonies were picked up to 4mL of LB medium and cultured at 37 ℃ overnight on a shaker at 220 rpm. After sequencing verification, pET28a-PaIPDH mutant recombinant bacteria are obtained.
Purifying PaIPDH mutant protein from broken supernatant of pET28a-PaIPDH mutant recombinant bacteria, and purifying with NAD+As a coenzyme, the activity of the expressed protein was measured in a 1mL cuvette. Containing 1mmol/L (-) -trans-isomenthenol and 10mmol/L NAD+Preheating 1mL of reaction system (50mmol/L glycine-sodium hydroxide buffer solution, pH10.0) to 40 ℃, adding a proper amount of alcohol dehydrogenase mutant, carrying out heat preservation reaction at 40 ℃, detecting absorbance change of NADH at 340nm on a spectrophotometer, recording the change value of absorbance within 1 minute, and calculating enzyme activity.
The activity of the obtained series of alcohol dehydrogenase mutants on (-) -trans-isopenthenol is improved by detecting the activity of the alcohol dehydrogenase PaIPDH through site-directed mutagenesis, wherein the glutamic acid at the 95 th position is replaced by phenylalanine (E95F), the valine at the 189 th position is replaced by tryptophan (V189W), the phenylalanine at the 195 th position is replaced by tryptophan (F195W), and the tyrosine at the 199 th position is replaced by valine (Y199V). On the basis, saturation mutation is carried out on some sites, and mutation points are combined to obtain mutants with obviously improved activity on (-) -trans-isopenthenol, and the sequences of the mutants and the activity of the mutants on the (-) -trans-isopenthenol are listed in a table 2.
TABLE 2 list of alcohol dehydrogenase mutant sequences and corresponding activity improvements
The alcohol dehydrogenase PaIPDH mutant amino acid has one of the following sequences:
(1) replacing glutamic acid at position 95 of the amino acid sequence shown as SEQ ID No.2 with valine (E95V);
(2) the glutamic acid at position 95 of the amino acid sequence shown as SEQ ID No.2 is replaced by phenylalanine (E95F);
(3) the glutamic acid at position 97 of the amino acid sequence shown as SEQ ID No.1 is replaced by methionine (E97M);
(4) the methionine at position 154 of the amino acid sequence shown as SEQ ID No.2 is replaced by histidine (M154H);
(5) replacing valine at position 189 of the amino acid sequence shown as SEQ ID No.2 with tryptophan (V189W);
(6) replacing valine at position 189 of the amino acid sequence shown as SEQ ID No.2 with isoleucine (V189I);
(7) replacing aspartic acid at position 191 of the amino acid sequence shown as SEQ ID No.2 with valine (D191V);
(8) substitution of methionine at position 194 of the amino acid sequence shown in SEQ ID No.2 with lysine (M194K);
(9) substitution of methionine at position 194 of the amino acid sequence shown in SEQ ID No.2 with asparagine (M194N);
(10) replacing phenylalanine at position 195 of the amino acid sequence shown as SEQ ID No.2 with tryptophan (F195W);
(11) replacing phenylalanine at position 195 of the amino acid sequence shown as SEQ ID No.2 with methionine (F195M);
(12) substitution of tyrosine 199 to valine (Y199V) of the amino acid sequence shown in SEQ ID No. 2;
(13) replacing tyrosine 199 th of the amino acid sequence shown as SEQ ID No.2 with histidine (Y199H);
(14) replacing glutamic acid at position 95 of the amino acid sequence shown as SEQ ID No.2 with valine (E95V), and replacing phenylalanine at position 208 with histidine (F208H);
(15) the glutamic acid at position 97 of the amino acid sequence shown as SEQ ID No.2 is replaced by methionine (E97M), and the methionine at position 154 is replaced by histidine (M154H);
(16) the methionine at position 194 of the amino acid sequence shown as SEQ ID No.2 is replaced by lysine (M194K), and the tyrosine at position 199 is replaced by serine (Y199W);
(17) substitution of methionine at position 194 with lysine (M194K), substitution of tyrosine at position 199 with histidine (Y199H), substitution of phenylalanine at position 208 with histidine (F208H) of the amino acid sequence shown in SEQ ID No. 2;
(18) the amino acid sequence shown in SEQ ID No.2 has the amino acid sequence with glutamic acid at position 95 substituted by phenylalanine (E95F), valine at position 189 substituted by tryptophan (V189W), phenylalanine at position 195 substituted by tryptophan (F195W) and tyrosine at position 199 substituted by valine (Y199V).
Example 3 expression and purification of recombinase PaIPDH mutant E95F/V189W/F195W/Y199V
The expression strain obtained in example 2, E.coli/pET28a-PaIPDHE95F/V189W/F195W/Y199VInoculated into LB liquid medium (tryptone: 10g/L, yeast extract: 5g/L, NaCl: 10g/L) containing 50. mu.g/mL kanamycin, shake-cultured at 220rpm at 37 ℃ for 24 hours, and inoculated at 1% inoculum size into 100mL TB liquid medium (tryptone: 12g/L, yeast extract: 24g/L, glycerol: 4mL/L, KH) containing 50. mu.g/mL kanamycin2PO4：2.31g/L，K2HPO412.54g/L), cultured in a shaker at 37 ℃ and 220rpm, when the optical density OD of the culture solution is600When the concentration reaches 0.6-0.8, 0.2mM IPTG is added for induction, and the culture is continued at 16 ℃ for 20-24 h. After completion of the culture, the culture solution was centrifuged at 8000 Xg and 4 ℃ to remove the supernatant, and the cells were washed twice with 0.9% physiological saline. Then purified buffer A (0.59 g/LNaH)2PO4·2H2O,5.8g/L Na2HPO4·12H2O,500mM NaCl, 5mM imidazole, 375. mu.L/L beta-mercaptoethanol, pH 7.4), the ratio of cells to buffer was 1: 20 (g/mL). After the resuspension was complete, the cells were sonicated (260W, 4s working, 6s pause). The disruption solution was centrifuged at 8000 Xg at 4 ℃ to remove the precipitate, and a supernatant containing the protein was obtained. The supernatant containing the target protein was poured onto a nickel column previously equilibrated with purification buffer a. Purification with buffer B (0.59g/L NaH)2PO4·2H2O,5.8g/L Na2HPO4·12H2O,500mM NaCl, 500mM imidazole, 375. mu.L/L beta-mercaptoethanol, pH 7.4-7.6) and purification buffer A are premixed for gradient elution with imidazole concentration of 0-250 mM. SDS-PAGE is carried out by a vertical electrophoresis apparatus, the concentration of the separation gel is 12.5%, and the collected eluted protein is detected, so that the purity of the mutant obtained by the method is over 90%, and the molecular weight is about 30 kDa. The appropriate eluate was collected, concentrated by ultrafiltration using a 10kDa ultrafiltration membrane at 4 ℃ and purified buffer C (0.59g/L NaH)2PO4·2H2O,5.8g/L Na2HPO4·12H2O,200mM NaCl, 2mM DTT), and finally carrying out ultrafiltration concentration to 1mL of protein solution by using a 10kDa ultrafiltration membrane at 4 ℃, adding 20% of glycerol and placing at-80 ℃ for later use.
Example 4 recombinant hydroxydehydrogenase PaIPDH and mutant E95F/V189W/F195W/Y199V catalytic dehydrogenation activity of substrate
The enzyme activity was measured in a 1mL cuvette, and 10. mu.L of 100mM substrate series (the structure is shown in Table 3) and 200. mu.L of 50mM NAD were added to 740. mu.L of glycine-NaOH buffer (50mM, pH10.0)+50 μ L of diluted pure enzyme. Detecting the absorbance change of NADH at 340nm on a spectrophotometer at 40 ℃, recording the change value of absorbance within 1 minute, and calculating the enzyme activity.
TABLE 3 Activity of PaIPDH catalytic series of substrates
Example 5 recombinant Hydroxydehydrogenase PaIPDHE95F/V189W/F195W/Y199VCatalytic synthesis of (-) -isomenthenone
pET21a-P450camY96F/Y247LPdx-Pdr and pET28a-PaIPDH mutant pET28a-PaIPDHE95F/V189W/F195W/Y199VThe two plasmids with different resistance were introduced into E.coli BL21(DE), and then plated to double-resistant platesThe plates were incubated at 37 ℃ for 12 h. The obtained monoclonal colonies were picked up to 4mL of LB medium containing 100. mu.g/mL of ampicillin and 50. mu.g/mL of kanamycin, cultured, and shaken at 37 ℃ and 220rpm overnight. The bacterial solution was inoculated from a test tube at an inoculum size of 1% to a shaking flask LB medium containing 100. mu.g/mL ampicillin and 50. mu.g/mL kanamycin, and cultured at 37 ℃ to OD600After 0.8, 0.2mM IPTG, 0.1mM FeCl were added3And 0.2mM 5-aminolevulinic acid, followed by incubation at 16 ℃ and 180rpm for a further 24 h. After completion of the culture, the culture solution was centrifuged at 8000 Xg and 4 ℃ to remove the supernatant, and the cells were washed twice with 0.9% physiological saline. The harvested pellet was resuspended with 50mM KPB (pH 7.6) to a cell content of 20g/L, and 1L of the cell suspension was added to a 5L three-necked flask, followed by addition of 158.9mg of (-) -limonene (final concentration 8mM), reaction at 25 ℃ and 200rpm for 18 hours, and the concentration of (-) -isomenthenone product was 128.6mg L-1,. After the reaction is finished, the product is extracted by using equal volume of ethyl acetate and dried for 8 hours by using anhydrous sodium sulfate, and the solvent is removed by reduced pressure rotary evaporation at the temperature of 20 ℃ to obtain a yellow crude product. All crude products obtained from the 9 batches of reactions are combined and purified by silica gel column chromatography to obtain a product (-) -isomenthenone, and the mobile phase is petroleum ether/ethyl acetate with the ratio of 100: 1. 529.5mg of yellowish liquid is obtained by separation, the separation yield is 41%, and the purity is more than 92%.
The specific applications of the mutant E95F/V189W/F195W/Y199V (i.e., the glutamic acid at position 95 of the amino acid sequence shown in SEQ ID No.2 is replaced by phenylalanine, the valine at position 189 is replaced by tryptophan, the phenylalanine at position 195 is replaced by tryptophan, and the tyrosine at position 199 is replaced by valine) in the above examples 4-5 are taken as examples to illustrate the catalytic activity of the substrate in dehydrogenation reaction, the catalytic synthesis of (-) -isomenthenone and the like. It should be noted that: as shown in Table 2, the mutant E95F/V189W/F195W/Y199V is only one of the alcohol dehydrogenase mutants of the invention, and as shown in Table 2, other kinds of alcohol dehydrogenase mutants have much higher specific activity than that of the protein consisting of the amino acid sequence shown in SEQ ID No.2, so that the technicians in the field know that other kinds of alcohol dehydrogenase mutants can catalyze the dehydrogenation activity of the substrate and catalyze and synthesize (-) -isomenthenone, and have the technical effect superior to that of the protein consisting of the amino acid sequence shown in SEQ ID No. 2. The embodiment of the invention is only illustrated by taking the mutant E95F/V189W/F195W/Y199V as an example.
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Sequence listing
<110> university of eastern China, Baifuan enzyme technology, Suzhou, Ltd
<120> alcohol dehydrogenase mutant and application thereof in cyclic terpene ketone synthesis
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 762
<212> DNA
<213> Pseudomonas aeruginosa
<400> 1
atgagcaaac ttctttccgg ccaggtcgcg ctggtcactg gcggtgcggc gggcatcggc 60
cgcgctaccg cgcaggcctt cgccgccgcc ggggtcaagg tggtggtcgc cgacctggac 120
agcgccggcg gcgagggcac ggtcgaagcg atccgccagg caggtggcga agccgtcttc 180
attcgctgcg acgtcacccg cgacgccgag gtcaaggcgc tggtagaggg ttgcgcggcg 240
gcctacggcc gtctcgacta cgccttcaac aacgccggta tcgagatcga gcagggcaag 300
ctggccgacg gcaacgaagc cgagttcgac gccatcatgg ctgtcaacgt gaagggcgtc 360
tggttgtgca tgaagcacca gatcccgctg atgctggccc agggcggtgg cgcgatcgtc 420
aacaccgcct cggtcgccgg gctcggcgcg gcgccgaaga tgagcatcta cgctgcttcc 480
aagcacgcgg tgatcggcct gaccaaatcg gcggcgatcg agtacgcgaa gaagggcatc 540
cgcgtcaacg ccgtgtgtcc ggcggtgatc gacaccgaca tgttccgccg cgcctacgag 600
gccgatccgc gcaaggccga gttcgccgcc gcgatgcatc cgctgggtcg ggtcgggcgg 660
gtcgaagaaa tcgccgccgc ggtgctctat ctgtgcagcg acaacgcagg cttcaccacc 720
ggtatcgcct tgccggtgga cggcggggcg acggcgatct ga 762
<210> 2
<211> 253
<212> PRT
<213> Pseudomonas aeruginosa
<400> 2
Met Ser Lys Leu Leu Ser Gly Gln Val Ala Leu Val Thr Gly Gly Ala
1 5 10 15
Ala Gly Ile Gly Arg Ala Thr Ala Gln Ala Phe Ala Ala Ala Gly Val
20 25 30
Lys Val Val Val Ala Asp Leu Asp Ser Ala Gly Gly Glu Gly Thr Val
35 40 45
Glu Ala Ile Arg Gln Ala Gly Gly Glu Ala Val Phe Ile Arg Cys Asp
50 55 60
Val Thr Arg Asp Ala Glu Val Lys Ala Leu Val Glu Gly Cys Ala Ala
65 70 75 80
Ala Tyr Gly Arg Leu Asp Tyr Ala Phe Asn Asn Ala Gly Ile Glu Ile
85 90 95
Glu Gln Gly Lys Leu Ala Asp Gly Asn Glu Ala Glu Phe Asp Ala Ile
100 105 110
Met Ala Val Asn Val Lys Gly Val Trp Leu Cys Met Lys His Gln Ile
115 120 125
Pro Leu Met Leu Ala Gln Gly Gly Gly Ala Ile Val Asn Thr Ala Ser
130 135 140
Val Ala Gly Leu Gly Ala Ala Pro Lys Met Ser Ile Tyr Ala Ala Ser
145 150 155 160
Lys His Ala Val Ile Gly Leu Thr Lys Ser Ala Ala Ile Glu Tyr Ala
165 170 175
Lys Lys Gly Ile Arg Val Asn Ala Val Cys Pro Ala Val Ile Asp Thr
180 185 190
Asp Met Phe Arg Arg Ala Tyr Glu Ala Asp Pro Arg Lys Ala Glu Phe
195 200 205
Ala Ala Ala Met His Pro Leu Gly Arg Val Gly Arg Val Glu Glu Ile
210 215 220
Ala Ala Ala Val Leu Tyr Leu Cys Ser Asp Asn Ala Gly Phe Thr Thr
225 230 235 240
Gly Ile Ala Leu Pro Val Asp Gly Gly Ala Thr Ala Ile
245 250
<210> 3
<211> 2879
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
atgacgactg aaaccataca aagcaacgcc aatcttgccc ctctgccacc ccatgtgcca 60
gagcacctgg tattcgactt cgacatgtac aatccgtcga atctgtctgc cggcgtgcag 120
gaggcctggg cagttctgca agaatcaaac gtaccggatc tggtgtggac tcgctgcaac 180
ggcggacact ggatcgccac tcgcggccaa ctgatccgtg aggcctatga agattaccgc 240
cacttttcca gcgagtgccc gttcatccct cgtgaagccg gcgaagcctt tgacttcatt 300
cccacctcga tggatccgcc cgagcagcgc cagtttcgtg cgctggccaa ccaagtggtt 360
ggcatgccgg tggtggataa gctggagaac cggatccagg agctggcctg ctcgctgatc 420
gagagcctgc gcccgcaagg acagtgcaac ttcaccgagg actacgccga acccttcccg 480
atacgcatct tcatgctgct cgcaggtcta ccggaagaag atatcccgca cttgaaatac 540
ctaacggatc agatgacccg tccggatggc agcatgacct tcgcagaggc caaggaggcg 600
ctctacgact atctgatacc gatcatcgag caacgcaggc agaagccggg aaccgacgct 660
atcagcatcg ttgccaacgg ccaggtcaat gggcgaccga tcaccagtga cgaagccaag 720
aggatgtgtg gcctgttact gctgggcggc ctggatacgg tggtcaattt cctcagcttc 780
agcatggagt tcctggccaa aagcccggag catcgccagg agctgatcga gcgtcccgag 840
cgtattccag ccgcttgcga ggaactactc cggcgcttct cgctggttgc cgatggccgc 900
atcctcacct ccgattacga gtttcatggc gtgcaactga agaaaggtga ccagatcctg 960
ctaccgcaga tgctgtctgg cctggatgag cgcgaaaacg cctgcccgat gcacgtcgac 1020
ttcagtcgcc aaaaggtttc acacaccacc tttggccacg gcagccatct gtgccttggc 1080
cagcacctgg cccgccggga aatcatcgtc accctcaagg aatggctgac caggattcct 1140
gacttctcca ttgccccggg tgcccagatt cagcacaaga gcggcatcgt cagcggcgtg 1200
caggcactcc ctctggtctg ggatccggcg actaccaaag cggtatgaga attcaaggag 1260
atataccatg tctaaagtag tgtatgtgtc acatgatgga acgcgtcgcg aactggatgt 1320
ggcggatggc gtcagcctga tgcaggctgc agtctccaat ggtatctacg atattgtcgg 1380
tgattgtggc ggcagcgcca gctgtgccac ctgccatgtc tatgtgaacg aagcgttcac 1440
ggacaaggtg cccgccgcca acgagcggga aatcggcatg ctggagtgcg tcacggccga 1500
actgaagccg aacagcaggc tctgctgcca gatcatcatg acgcccgagc tggatggcat 1560
cgtggtcgat gttcccgata ggcaatggta agagctcaag gagatatacc atgaacgcaa 1620
acgacaacgt ggtcatcgtc ggtaccggac tggctggcgt tgaggtcgcc ttcggcctgc 1680
gcgccagcgg ctgggaaggc aatatccggt tggtggggga tgcgacggta attccccatc 1740
acctaccacc gctatccaaa gcttacttgg ccggcaaagc cacagcggaa agcctgtacc 1800
tgagaacccc agatgcctat gcagcgcaga acatccaact actcggaggc acacaggtaa 1860
cggctatcaa ccgcgaccga cagcaagtaa tcctatcgga tggccgggca ctggattacg 1920
accggctggt attggctacc ggagggcgtc caagacccct accggtggcc agtggcgcag 1980
ttggaaaggc gaacaacttt cgatacctgc gcacactcga ggacgccgag tgcattcgcc 2040
ggcagctgat tgcggataac cgtctggtgg tgattggtgg cggctacatt ggccttgaag 2100
tggctgccac cgccatcaag gcgaacatgc acgtcaccct gcttgatacg gcagcccggg 2160
ttctggagcg ggttaccgcc ccgccggtat cggcctttta cgagcaccta caccgcgaag 2220
ccggcgttga catacgaacc ggcacgcagg tgtgcgggtt cgagatgtcg accgaccaac 2280
agaaggttac tgccgtcctc tgcgaggacg gcacaaggct gccagcggat ctggtaatcg 2340
ccgggattgg cctgatacca aactgcgagt tggccagtgc ggccggcctg caggttgata 2400
acggcatcgt gatcaacgaa cacatgcaga cctctgatcc cttgatcatg gccgtcggcg 2460
actgtgcccg atttcacagt cagctctatg accgctgggt gcgtatcgaa tcggtgccca 2520
atgccttgga gcaggcacga aagatcgccg ccatcctctg tggcaaggtg ccacgcgatg 2580
aggcggcgcc ctggttctgg tccgatcagt atgagatcgg attgaagatg gtcggactgt 2640
ccgaagggta cgaccggatc attgtccgcg gctctttggc gcaacccgac ttcagcgttt 2700
tctacctgca gggagaccgg gtattggcgg tcgatacagt gaaccgtcca gtggagttca 2760
accagtcaaa acaaataatc acggatcgtt tgccggttga accaaaccta ctcggtgacg 2820
aaagcgtgcc gttaaaggaa atcatcgccg ccgccaaagc tgaactgagt agtgcctga 2879
Claims (10)
1. An alcohol dehydrogenase mutant, which is a protein corresponding to a new amino acid sequence formed by replacing one or more amino acid residues of glutamic acid at position 95, glutamic acid at position 97, methionine at position 154, valine at position 189, aspartic acid at position 191, methionine at position 194, phenylalanine 195, tyrosine at position 199 and phenylalanine at position 208 of an amino acid sequence shown in SEQ ID No.2 with other amino acid residues, and the derived protein has higher catalytic performance and stability than the protein consisting of the amino acid sequence shown in SEQ ID No. 2.
2. The alcohol dehydrogenase mutant according to claim 1, which is a protein consisting of any one of the following amino acid sequences:
(1) replacing glutamic acid at position 95 of the amino acid sequence shown as SEQ ID No.2 with valine;
(2) the glutamic acid at the 95 th site of the amino acid sequence shown as SEQ ID No.2 is replaced by phenylalanine;
(3) the glutamic acid at position 97 of the amino acid sequence shown as SEQ ID No.1 is replaced by methionine;
(4) the methionine at position 154 of the amino acid sequence shown as SEQ ID No.2 is replaced by histidine;
(5) replacing valine at position 189 of the amino acid sequence shown as SEQ ID No.2 with tryptophan;
(6) replacing valine at position 189 of the amino acid sequence shown as SEQ ID No.2 with isoleucine;
(7) replacing aspartic acid at position 191 of the amino acid sequence shown as SEQ ID No.2 with valine;
(8) substitution of methionine at position 194 of the amino acid sequence shown in SEQ ID No.2 with lysine;
(9) the 194 th methionine of the amino acid sequence shown as SEQ ID No.2 is replaced by asparagine;
(10) the 195 th phenylalanine of the amino acid sequence shown as SEQ ID No.2 is replaced by tryptophan;
(11) the 195 th phenylalanine of the amino acid sequence shown as SEQ ID No.2 is replaced by methionine;
(12) replacing tyrosine 199 of the amino acid sequence shown as SEQ ID No.2 with valine;
(13) replacing tyrosine 199 th position of the amino acid sequence shown as SEQ ID No.2 with histidine;
(14) the amino acid sequence shown as SEQ ID No.2 has valine substituted for glutamic acid at position 95 and histidine substituted for phenylalanine at position 208;
(15) the glutamic acid at position 97 of the amino acid sequence shown as SEQ ID No.2 is replaced by methionine, and the methionine at position 154 is replaced by histidine;
(16) the 194 th methionine of the amino acid sequence shown as SEQ ID No.2 is replaced by lysine, and the 199 th tyrosine is replaced by serine;
(17) the amino acid sequence shown as SEQ ID No.2 has the amino acid sequence with the substitution of methionine at position 194 to lysine, tyrosine at position 199 to histidine and phenylalanine at position 208 to histidine;
(18) the amino acid sequence shown in SEQ ID No.2 has the amino acid sequence with glutamic acid at position 95 replaced by phenylalanine, valine at position 189 replaced by tryptophan, phenylalanine at position 195 replaced by tryptophan and tyrosine at position 199 replaced by valine.
3. An isolated nucleic acid which is a nucleic acid molecule encoding an alcohol dehydrogenase mutant according to claim 1 or 2.
4. A recombinant expression plasmid comprising the nucleic acid of claim 3.
5. A recombinant expression transformant comprising the recombinant expression plasmid of claim 4.
6. A recombinant alcohol dehydrogenase mutant catalyst, wherein the recombinant alcohol dehydrogenase mutant catalyst is in any one of the following forms:
(1) culturing the recombinant expression transformant according to claim 5, and isolating a transformant cell containing the alcohol dehydrogenase mutant;
(2) culturing the recombinant expression transformant according to claim 5, and isolating a crude enzyme solution containing the alcohol dehydrogenase mutant;
(3) culturing the recombinant expression transformant according to claim 5, isolating a crude enzyme solution containing the alcohol dehydrogenase mutant, and freeze-drying the crude enzyme solution of the alcohol dehydrogenase mutant to obtain crude enzyme powder.
7. Use of an alcohol dehydrogenase mutant according to claim 1 or 2 or a recombinant alcohol dehydrogenase mutant catalyst according to claim 6 for catalyzing a dehydrogenation reaction of a hydroxy compound.
8. Use according to claim 7, wherein the hydroxy compound is selected from any one of the following compounds:
9. use of an alcohol dehydrogenase mutant or recombinant alcohol dehydrogenase mutant catalyst for the catalytic dehydrogenation of a cyclic terpene alcohol having the hydroxyl groups in the 3-and 6-positions for the production of a cyclic terpene ketone, according to claim 7.
10. The use of claim 7, wherein the alcohol dehydrogenase mutant or recombinant alcohol dehydrogenase mutant catalyst is used for catalyzing the dehydrogenation of (-) -trans-isomenthenol to produce (-) -isomenthenone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110421331.2A CN113151205A (en) | 2021-04-20 | 2021-04-20 | Alcohol dehydrogenase mutant and application thereof in cyclic terpene ketone synthesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110421331.2A CN113151205A (en) | 2021-04-20 | 2021-04-20 | Alcohol dehydrogenase mutant and application thereof in cyclic terpene ketone synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113151205A true CN113151205A (en) | 2021-07-23 |
Family
ID=76868790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110421331.2A Pending CN113151205A (en) | 2021-04-20 | 2021-04-20 | Alcohol dehydrogenase mutant and application thereof in cyclic terpene ketone synthesis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113151205A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019101926A1 (en) * | 2017-11-24 | 2019-05-31 | The University Of Manchester | Monoterpenoid biosynthesis |
| CN112159769A (en) * | 2020-09-30 | 2021-01-01 | 江南大学 | Genetically engineered bacterium for producing L-menthol and construction method and application thereof |
| CN112175849A (en) * | 2020-09-30 | 2021-01-05 | 江南大学 | Recombinant yeast with improved L-menthol yield |
| CN112513280A (en) * | 2018-05-25 | 2021-03-16 | 约翰·英尼斯中心 | Method for producing monoterpenes |
-
2021
- 2021-04-20 CN CN202110421331.2A patent/CN113151205A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019101926A1 (en) * | 2017-11-24 | 2019-05-31 | The University Of Manchester | Monoterpenoid biosynthesis |
| CN112513280A (en) * | 2018-05-25 | 2021-03-16 | 约翰·英尼斯中心 | Method for producing monoterpenes |
| CN112159769A (en) * | 2020-09-30 | 2021-01-01 | 江南大学 | Genetically engineered bacterium for producing L-menthol and construction method and application thereof |
| CN112175849A (en) * | 2020-09-30 | 2021-01-05 | 江南大学 | Recombinant yeast with improved L-menthol yield |
Non-Patent Citations (4)
| Title |
|---|
| ANDREW CURRIN 等: "Engineering the "Missing Link" in Biosynthetic (−)-Menthol Production: Bacterial Isopulegone Isomerase", ACS CATALYSIS, vol. 8 * |
| GENBANK: "NCBI Reference Sequence: WP_023122595.1", GENBANK * |
| GENBANK: "NCBI Reference Sequence: WP_126675978.1", GENBANK * |
| KERRY L. RINGER 等: "Monoterpene Metabolism. Cloning, Expression, and Characterization of (2)-Isopiperitenol/(2)-Carveol Dehydrogenase of Peppermint and Spearmint", PLANT PHYSIOLOGY, vol. 137 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chan et al. | The rare fluorinated natural products and biotechnological prospects for fluorine enzymology | |
| Rui et al. | Protein engineering of epoxide hydrolase from Agrobacterium radiobacter AD1 for enhanced activity and enantioselective production of (R)-1-phenylethane-1, 2-diol | |
| CN106676090B (en) | Cephalosporin C acylase mutant with improved thermal stability and construction method thereof | |
| US6261814B1 (en) | Carboxylic acid reductase, and methods of using same | |
| CN112877307B (en) | Amino acid dehydrogenase mutant and application thereof | |
| CN106754775B (en) | A kind of carbonyl reduction enzyme mutant and its gene and application | |
| CN110777125B (en) | Efficient preparation method of heterocyclic drug intermediate | |
| CN111996176B (en) | Carbonyl reductase mutant and application thereof | |
| Hummel et al. | Towards a large‐scale asymmetric reduction process with isolated enzymes: Expression of an (S)‐alcohol dehydrogenase in E. coli and studies on the synthetic potential of this biocatalyst | |
| WO2016138641A1 (en) | Generation and use of candida and carbonyl reductase thereof | |
| CN109055324B (en) | Improved ketoreductase and application thereof | |
| CN108048438B (en) | Halohydrin dehalogenase mutant and application thereof | |
| You et al. | Characterization of a prodigiosin synthetase PigC from Serratia marcescens jx-1 and its application in prodigiosin analogue synthesis | |
| CN114480512B (en) | Application of oxidoreductase and mutant thereof in biosynthesis of nootkatone | |
| CN113652407B (en) | Carbonyl reductase mutant and application thereof in asymmetric synthesis of chiral compound | |
| US20220049235A1 (en) | Engineering Bacteria for Ferulic Acid Production, Preparation Method and Use Thereof | |
| JP4998957B2 (en) | Hydroxylase gene and its use | |
| US11098287B2 (en) | 17β-hydroxysteroid dehydrogenase mutants and application thereof | |
| CN113201516A (en) | P-nitrobenzyl esterase mutant and application thereof | |
| CN112852895A (en) | Method for synthesizing (R) -3-amino-1-butanol by double-enzyme cascade catalysis | |
| EP2796548A1 (en) | Stereoselective production of (R)-3-quinuclidinol | |
| CN113151205A (en) | Alcohol dehydrogenase mutant and application thereof in cyclic terpene ketone synthesis | |
| CN107779459B (en) | Glucose dehydrogenase DNA molecule, vector, strain and application | |
| CN114277006B (en) | Alcohol dehydrogenase and application thereof in synthesis of chiral heterocyclic alcohol | |
| Zhang et al. | Identification of a novel ene reductase from Pichia angusta with potential application in (R)-levodione production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240424 Address after: Room 207, No. 8, Sihai Road Research Institute Road, Changshu Economic and Technological Development Zone, Suzhou City, Jiangsu Province Applicant after: SUZHOU BAIFU ENZYME TECHNOLOGY CO.,LTD. Country or region after: China Address before: 200237 No. 130, Meilong Road, Shanghai, Xuhui District Applicant before: EAST CHINA University OF SCIENCE AND TECHNOLOGY Country or region before: China Applicant before: SUZHOU BAIFU ENZYME TECHNOLOGY CO.,LTD. |
|
| TA01 | Transfer of patent application right |